UCB Pharmaceuticals, Inc.

A global biopharma focused on severe diseases in three therapeutic areas: Central nervous system Inflammation Oncology UCB also has a selective presence in primary care Global revenue of €3.6 billion in 2007 Operations in over 40 countries, supported by more than 10,000 staff Established in 1928, successful transformation from a hybrid specialty chemical company into a next generation biopharma leader Listed on the Euronext Brussels Stock Exchange Headquartered in Brussels, Belgium